Hydroxysafflor yellow A, by activating the AKT/GSK-3β/Fyn-Nrf2 axis, emerges as a potential therapeutic agent for ischemia/reperfusion (I/R)-induced AKI (29, 30). The gene discussed is AKT1; the disease is acute kidney injury.